人源瞬时受体电位M2型通道Nudix水解酶9同源结构域的提取和纯化

摸索人源瞬时受体电位M2型通道（TRPM2）羧基端Nudix水解酶9（NUDT9）同源结构域（NUDT9-H）的蛋白提取和纯化方法。 异丙基硫代半乳糖苷诱导表达的Rosetta（DE3）大肠埃希菌菌株经超声破碎和离心后，将收集到的上清液与GST磁珠结合并用还原型谷胱甘肽洗脱以抽提GST-NUDT9-H融合蛋白，浓缩离心后再经分子排阻色谱层析纯化，最后经凝血酶酶切并与GST磁珠结合即得NUDT9-H蛋白。 含有0.5%的十二烷基-β-D-麦芽糖苷（DDM）裂解溶液体系和0.025%的DDM分子排阻层析色谱溶液体系能够提高GST-NUDT9-H融合蛋白的稳定性，再按每2 mg融合蛋白加入1 U凝血酶切割24 h，即获得高纯度NUDT9-H蛋白。 NUDT9-H蛋白稳定性较差，提取和纯化体系中需添加DDM以稳定其构象从而提高目的蛋白的产量和纯度。      

Identification and characterization of a protective antigen,PlpB of bovine Pasteurella multocida strain LZ-PM

The Pasteurella multocida lipoprotein B (PlpB) was cloned from Pasteurella multocida (P. multocida) strain LZ-PM (serotype A) and expressed in Escherichia coli (E. coli). Sequence analysis showed that PlpB from different strains of P. multocida exhibited 80.8–99.4% sequence identity to each other, suggesting that PlpB might serve as a cross-protective antigen. The purified PCR product of PlpB gene consisting of 831 base pairs was inserted into the pET-32a (+) plasmid, and then transferred into E. coli. The protective immunity conferred by recombinant PlpB (rPlpB) on mice was evaluated. The results showed that mice immunized with 200 μg of purified rPlpB were protected (60% survival rate) against challenge infection with 1 MLD of P. multocida strain LZ-PM. In conclusion, our data indicated that the PlpB protein may be a potential target as a candidate subunit vaccine for P. multocida infection.     

Stable emulsion (SE) alone is an effective adjuvant for a recombinant,baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial

BackgroundInfluenza A viruses of the H5 subtype have been identified as important targets for development of vaccines. Achievement of potentially protective antibody responses against pandemic strains has usually required the use of adjuvants.ObjectivesWe evaluated a candidate A/Indonesia/05/2005 (H5) vaccine generated by baculovirus expression of recombinant hemagglutinin (HA) protein with or without stable emulsion (SE) as an adjuvant.MethodsHealthy subjects 18–49 years old were randomized (1:1:1:1) to receive two doses of rHA at 7.5 ug per dose (no adjuvant), or 3.8 ug, 7.5 ug, or 15 ug per dose formulated with 2% SE separated by 21 days, and serum from day 0, 21, 42, and 201 assessed by hemagglutination-inhibition.Results341 subjects were enrolled in the study and 321 received two doses of vaccine. Vaccination was well tolerated in all groups. After two doses, seroconversion was noted in only 9% (95% confidence interval 4%, 17%) of recipients of unadjuvanted vaccine at 7.5 ug, but in 70% (59%, 80%), 76% (65%, 85%), and 83% (73%, 91%) of those receiving adjuvanted vaccine at 3.8 ug, 7.5 ug, or 15 ug respectively.ConclusionsStable emulsion alone is an effective adjuvant for rH5 vaccine in healthy adults. All three adjuvanted dose groups met the current criterion for seroconversion rate for pandemic vaccines. This dose-ranging study also identified a group (15 ug per dose formulated with 2% SE) that met the criteria for both seroconversion and percentage of subjects achieving an HI antibody titer ⩾ 40. These Phase 2 data support the further clinical development of SE adjuvanted Panblok H5.Clinical trial registration: NCT01612000.The protocol was approved by the relevant Institutional Review Board for each study site, and the study was conducted in accordance with the Declaration of Helsinki, International Conference of Harmonisation – Good Clinical Practice, and all applicable laws and regulations. All participants provided written informed consent before study procedures.     

SD大鼠羊水间充质干细胞向神经样细胞体外诱导分化

目的:探讨体外诱导羊水间充质干细胞(AF-MSCs)分化成神经干细胞.方法:10只SD怀孕大鼠,180-240 g,胎龄16d,过量腹腔麻醉致死,开腹全部切除子宫,在无菌的条件下抽取全羊水,采用贴壁法分离AF-MSCs,体外培养扩增,观察细胞生长特性,流式细胞仪检测AF-MSCs表面抗原表达及细胞周期.取第3代AF-MSCs,加入预诱导液(DMEM/F12、100 mL/L FBS、1 mmol/Lβ-MEM)诱导24 h,然后加入诱导液(DMEM/F12、100 mL/L FBS、5 mmol/L β-MEM)诱导24 h,最后在分化维持培养液(DMEM/F12、20μg/L EGF、20μg/L bFGF)中培养,行免疫荧光染色,检测NSE和GFAP的表达.结果:成功分离、培养和传代SD大鼠AF-MSCs,流式细胞术检测提示大鼠AF-MSCs的G0/G1期细胞比例约为87.5%、S+G2+M期比例为12.5%,表达CD44为98.3%、GD29为70%、和CD105为33.2%、不表达CD45为0.5%,CD34为1%,DLA-DR(MHC class Ⅱ)为0.1%.诱导后,AF-MSCs能表达神经细胞标示物NSE和GFAP,且可在体外继续存活2 wk左右.结论:羊水中也存在MSCs,与其他来源的MSCs特点相符:羊水可以作为一种新的胎儿MSCs来源,而且能在体外诱导分化为神经细胞.     

细粒棘球绦虫重组BCG-Eg95疫苗诱导小鼠脾细胞淋巴因子变化的研究

目的 探讨细粒棘球绦虫（Eg）重组BCG-Eg95疫苗免疫后对受攻击小鼠的包囊减重率及脾细胞淋巴因子的影响。方法 细粒棘球绦虫重组BCG-Eg95疫苗分别采用皮下注射、鼻腔内接种、口服灌胃和肌肉注射4种途径免疫BALB/C小鼠，免疫后8周用Eg原头节攻击感染，50个Eg原头节/每只小鼠，感染后18周剖杀小鼠，分离并称重细粒棘球蚴，计算包囊减重率；取脾，分离脾细胞，用Eg粗抗原（EgAg）或伴刀豆球蛋白A（ConA）刺激培养，收集脾细胞培养上清液，检测脾细胞培养上清液的白介素-2（IL-2）、γ干扰素（IFN-γ）、肿瘤坏死因子α（TNF-α）和白介素-4（IL-4）水平。同时设卡介苗（BCG）和磷酸盐缓冲液（PBS）对照。 结果 以上4种疫苗接种组的包囊减重率分别为45.77%、18.20%、88.05%和92.46%；疫苗肌肉接种组的IL-2、IFN-γ和TNF-α均较PBS对照为高，分别为（30.0±0）pg/ml、（65.0±0）pg/ml和（425.0±10.7） pg/ml， IL-4低于PBS对照组， 为（10.0±0） pg/ml。 结论 细粒棘球绦虫重组BCG-Eg95疫苗诱导小鼠产生辅助性T细胞1型（Th1）反应，从而对抗Eg原头节攻击感染。     

重组组织型纤溶酶原激活剂静脉溶栓治疗急性心肌梗死20例分析

目的 :探讨重组组织型纤溶酶原激活剂 (rt PA)静脉溶栓治疗急性心肌梗死 (AMI)的疗效及安全性。方法 :选择 2 0例AMI患者应用rt PA静脉溶栓治疗 ,观察临床症状、心电图、心肌酶谱的变化 ,判断冠状动脉再通率。结果 :① 2 0例AMI患者 ,冠状动脉再通 12例 ,再通率 6 0 %,其中发病 6h以内溶栓再通率 87.5 %(7/ 8) ,发病 6～ 2 4h溶栓再通率 4 1.7%(5 / 12 ) ,两者相比差异有显著性意义 (P <0 .0 5 )。②≤ 6 5岁患者的血管再通率与不良反应发生率与 >6 5岁组相比差异无显著性意义 (P >0 .0 5 )。结论 :rt PA静脉溶栓治疗AMI是一种安全、有效的方法 ,宜提倡急诊室溶栓。 >6 5岁患者行静脉溶栓治疗是安全可行的 ,但要根据患者的具体情况而定。     

重组人心钠肽治疗急性心力衰竭的临床研究

目的：探讨重组人心钠肽治疗急性心力衰竭疗效。方法：对自2011年5月～2013年2月我院收治的急性心力衰竭患者应用重组人心钠肽治疗,于用药前后监测患者的血流动力学参数。结果：66例患者59例症状缓解,显效27例,有效32例,无效7例,有效率89．39％。结论：重组人心钠肽是治疗急性心力衰竭疗效可靠的药物,安全性高。